Table 2 Baseline characteristics in patients with CABG surgery based on quartiles of METS-IR
Variables | Quartile 1 (N = 276) | Quartile 2(N = 277) | Quartile 3 (N = 276) | Quartile 4 (N = 271) | p-value |
|---|---|---|---|---|---|
METS-IR | 32.30 (29.93–33.74) | 37.54 (36.48–38.60) | 41.80 (40.71–43.28) | 48.15 (45.98–51.22) |  < 0.001 |
General conditions | |||||
Age (years) | 64.65 ± 7.80 | 62.82 ± 8.05 | 61.95 ± 7.93 | 61.90 ± 9.05 |  < 0.001 |
Male, n (%) | 171 (62.0) | 190 (68.6) | 196 (71.0) | 203 (74.9) | 0.010 |
BMI (kg/m2) | 21.66 ± 2.04 | 24.57 ± 1.48 | 26.54 ± 1.93 | 29.93 ± 2.59 |  < 0.001 |
LVEF (%) | 60.00 (53.00–66.00) | 60.00 (55.00–65.00) | 60.00 (53.00–65.00) | 60.00 (53.00–65.00) | 0.195 |
FH-CAD, n (%) | 47 (17.1) | 66 (23.8) | 53 (19.2) | 49 (18.1) | 0.202 |
Admission for MI, n (%) | 46 (16.7) | 46 (16.6) | 57 (20.7) | 48 (17.7) | 0.566 |
Medical history, n (%) | |||||
Previous MI | 51 (18.5) | 54 (19.5) | 61 (22.1) | 49 (18.1) | 0.633 |
Pervious stroke | 41 (14.9) | 39 (14.1) | 41 (14.9) | 44 (16.2) | 0.915 |
Previous PCI | 23 (8.3) | 26 (9.4) | 32 (11.6) | 33 (12.2) | 0.404 |
Hypertension | 160 (58.0) | 168 (60.6) | 185 (67.0) | 180 (66.4) | 0.074 |
DM | 63 (22.8) | 74 (26.7) | 103 (37.3) | 123 (45.4) |  < 0.001 |
Hyperlipidemia | 83 (30.1) | 88 (31.8) | 103 (37.3) | 98 (36.2) | 0.219 |
Laboratory text | |||||
FBG (mmol/L) | 5.04 (4.48–5.74) | 5.20 (4.63–6.38) | 5.54 (4.83–6.99) | 6.09 (4.96–8.45) |  < 0.001 |
TC (mmol/L) | 4.24 (3.58–5.11) | 4.05 (3.45–4.85) | 4.00 (3.49–5.02) | 4.07 (3.44–4.90) | 0.164 |
LDL-C (mmol/L) | 2.48 (1.87–3.02) | 2.36 (1.93–2.95) | 2.52 (2.03–3.16) | 2.44 (1.90–3.02) | 0.382 |
HDL-C (mmol/L) | 1.25 (1.09–1.43) | 1.13 (1.01–1.27) | 1.07 (0.94–1.19) | 1.00 (0.87–1.14) |  < 0.001 |
TG (mmol/L) | 1.06 (0.81–1.38) | 1.22 (0.95–1.68) | 1.43 (1.09–1.68) | 1.50 (1.18–2.07) |  < 0.001 |
eGFR(ml/min/1.73m2) | 107.64 ± 26.03 | 106.50 ± 26.16 | 106.59 ± 26.18 | 106.20 ± 39.80 | 0.949 |
UA (µmol/L) | 295.29 ± 77.03 | 309.8 ± 85.08 | 309.25 ± 83.64 | 335.95 ± 96.24 |  < 0.001 |
Cardiovascular medications, n (%) | |||||
Antiplatelet drugs | 275 (99.6) | 271 (97.8) | 275 (98.7) | 268 (98.9) | 0.090 |
Statins | 219 (79.3) | 235 (84.8) | 224 (81.2) | 220 (81.2) | 0.401 |
Beta-blockers | 250 (90.6) | 247 (89.2) | 240 (87.0) | 236 (87.1) | 0.482 |
ACEI/ARB | 33 (12.0) | 41 (14.8) | 43 (15.6) | 55 (20.3) | 0.059 |
Hypoglycemic drugs | 43 (15.6) | 51 (18.4) | 68 (24.6) | 100 (36.9) |  < 0.001 |
Outcomes, n (%) | |||||
MACE | 48 (17.4) | 51 (18.4) | 62 (22.5) | 82 (30.3) | 0.001 |
All-cause death | 19 (6.9) | 15 (5.4) | 18 (6.5) | 22 (8.1) | 0.654 |
Coronary artery revascularization | 11 (4.0) | 13 (4.7) | 16 (5.8) | 18 (6.6) | 0.513 |
Non-fatal MI | 14 (5.1) | 14 (5.1) | 15 (5.4) | 27 (10.0) | 0.047 |
stroke | 8 (2.9) | 14 (5.1) | 19 (6.9) | 24 (8.9) | 0.022 |
Cardiovascular death | 6 (2.2) | 7 (2.5) | 7 (2.5) | 10 (3.7) | 0.718 |